MD20160018A2 - Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin - Google Patents

Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin Download PDF

Info

Publication number
MD20160018A2
MD20160018A2 MDA20160018A MD20160018A MD20160018A2 MD 20160018 A2 MD20160018 A2 MD 20160018A2 MD A20160018 A MDA20160018 A MD A20160018A MD 20160018 A MD20160018 A MD 20160018A MD 20160018 A2 MD20160018 A2 MD 20160018A2
Authority
MD
Moldova
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
compounds
isoquinoline compounds
Prior art date
Application number
MDA20160018A
Other languages
English (en)
Russian (ru)
Other versions
MD4793C1 (ro
MD4793B1 (ro
Inventor
Джеймс Эдвард Пол Дэвидсон
Джеймс Брук МЮРРЕЙ
Ай-Джен ЧЕНЬ
Клэр Уолмсли
Марк ДОДСУОРТ
Йоханнес В.Г. МЕЙССНЕР
Пол БРОГ
Имре ФЕЕШ
Янош Татаи
Миклош Ньергеш
Андрас КОЦКИ
Золтан Славик
Оливье Женест
Тиран Арно Ле
Дигуарье Тьерри Ле
Жан-Мишель ХЕНЛИН
Жером-Бенуа Старк
Анна-Франсуаза ГИЙЮЗИС
Нантей Гийом Де
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier, Vernalis (R&D) Ltd filed Critical Les Laboratoires Servier
Publication of MD20160018A2 publication Critical patent/MD20160018A2/ro
Publication of MD4793B1 publication Critical patent/MD4793B1/ro
Publication of MD4793C1 publication Critical patent/MD4793C1/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Prezenta invenţie se referă la compuşi noi de izoindolină sau izochinolină, la un procedeu de obţinere a lor şi la compoziţii farmaceutice care îi conţin.Prezenta invenţie se referă, în special, la compuşii cu formula (I):Compuşii conform prezentei invenţii au proprietăţi pro-apoptotice, fapt ce permite utilizarea lor în patologii care implică un defect în apoptoză, cum ar fi, de exemplu, în tratamentul cancerului, bolilor autoimune şi bolilor sistemului imunitar.
MDA20160018A 2013-07-23 2014-07-22 Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin MD4793C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2014/065764 WO2015011164A1 (en) 2013-07-23 2014-07-22 New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
MD20160018A2 true MD20160018A2 (ro) 2016-07-31
MD4793B1 MD4793B1 (ro) 2022-02-28
MD4793C1 MD4793C1 (ro) 2022-09-30

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160018A MD4793C1 (ro) 2013-07-23 2014-07-22 Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin

Country Status (49)

Country Link
US (3) US9809574B2 (ro)
EP (1) EP3024826B1 (ro)
JP (1) JP6395829B2 (ro)
KR (1) KR102008431B1 (ro)
CN (2) CN109456324B (ro)
AP (1) AP2016008989A0 (ro)
AR (1) AR097009A1 (ro)
AU (1) AU2014295101B2 (ro)
BR (1) BR112016001080B1 (ro)
CA (1) CA2919572C (ro)
CL (1) CL2016000148A1 (ro)
CR (1) CR20160030A (ro)
CU (1) CU24352B1 (ro)
CY (1) CY1121247T1 (ro)
DK (1) DK3024826T3 (ro)
DO (1) DOP2016000009A (ro)
EA (1) EA032301B1 (ro)
ES (1) ES2711371T3 (ro)
FR (1) FR3008977A1 (ro)
GE (1) GEP20207070B (ro)
HK (1) HK1218754A1 (ro)
HR (1) HRP20190277T1 (ro)
HU (1) HUE041443T2 (ro)
IL (1) IL243449A0 (ro)
JO (1) JO3457B1 (ro)
LT (1) LT3024826T (ro)
MA (1) MA38801B1 (ro)
MD (1) MD4793C1 (ro)
ME (1) ME03346B (ro)
MX (1) MX365373B (ro)
MY (1) MY193619A (ro)
NI (1) NI201600016A (ro)
NZ (1) NZ716155A (ro)
PE (1) PE20160241A1 (ro)
PH (1) PH12016500034B1 (ro)
PL (1) PL3024826T3 (ro)
PT (1) PT3024826T (ro)
RS (1) RS58344B1 (ro)
RU (1) RU2689305C2 (ro)
SA (1) SA516370439B1 (ro)
SG (1) SG11201600205XA (ro)
SI (1) SI3024826T1 (ro)
TN (1) TN2016000003A1 (ro)
TR (1) TR201819155T4 (ro)
TW (1) TWI560184B (ro)
UA (1) UA117490C2 (ro)
UY (1) UY35664A (ro)
WO (1) WO2015011164A1 (ro)
ZA (1) ZA201600198B (ro)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX381425B (es) 2016-04-20 2025-03-12 Bristol Myers Squibb Co Compuestos heterociclicos biciclicos sustituidos.
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente
AU2020381792A1 (en) * 2019-11-15 2022-06-30 Wuhan Ll Science And Technology Development Co., Ltd. Rock inhibitor, preparation method therefor and use thereof
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
WO2022178218A1 (en) 2021-02-19 2022-08-25 Mevion Medical Systems, Inc. Gantry for a particle therapy system
KR20240152365A (ko) 2022-02-24 2024-10-21 르 라보레또레 쎄르비에르 5-[7-(3,4-디히드로-1h-이소퀴놀린-2-카르보닐)-1,2,3,4-테트라히드로이소퀴놀린-6-일]-1h-피롤-3-카르복스아미드유도체, 그를 함유하는 제약 조성물 및 아폽토시스촉진제로서의 그의 용도
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
CN121001985A (zh) * 2023-03-31 2025-11-21 三井化学株式会社 氨基甲酸酯化合物
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093297A2 (en) 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004096774A1 (en) * 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
AU2005277223C1 (en) * 2004-08-20 2009-05-21 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
WO2006087309A1 (en) * 2005-02-15 2006-08-24 Novo Nordisk A/S 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters
JP5496877B2 (ja) 2007-04-16 2014-05-21 アッヴィ・インコーポレイテッド 7−置換インドールMcl−1阻害薬
JP2011518109A (ja) 2007-11-30 2011-06-23 ビオタ サイエンティフィック マネージメント ピーティーワイ リミテッド 抗菌剤としてのテトラヒドロ−イソキノリンppat阻害剤
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
WO2009102463A2 (en) 2008-02-14 2009-08-20 Connor Reynolds Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
AU2012355623A1 (en) * 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2798432A4 (en) 2011-12-27 2015-07-22 Intel Corp METHODS AND SYSTEMS FOR CONTROLLING POWER SUPPLY NETWORKS DURING AN ACTIVE STATE OF A PERIODICALLY TRIGGERED DOMAIN IN ACCORDANCE WITH PERIODICALLY RELEASED DOMAIN LOADING CONDITIONS
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
ES2711371T3 (es) 2019-05-03
CY1121247T1 (el) 2020-05-29
TWI560184B (en) 2016-12-01
EA032301B1 (ru) 2019-05-31
ZA201600198B (en) 2019-07-31
UY35664A (es) 2015-01-30
CA2919572C (en) 2017-06-20
NZ716155A (en) 2019-05-31
TW201504228A (zh) 2015-02-01
CL2016000148A1 (es) 2016-08-12
ME03346B (me) 2019-10-20
AU2014295101A1 (en) 2016-02-04
SA516370439B1 (ar) 2019-06-27
CN109456324A (zh) 2019-03-12
DOP2016000009A (es) 2016-03-15
US20160194304A1 (en) 2016-07-07
HUE041443T2 (hu) 2019-05-28
CN109456324B (zh) 2022-04-22
NI201600016A (es) 2016-02-11
CU24352B1 (es) 2018-07-05
PL3024826T3 (pl) 2019-05-31
MX2016000904A (es) 2016-04-25
CN105431422B (zh) 2019-08-30
RU2016106003A (ru) 2017-08-28
PT3024826T (pt) 2019-01-28
MA38801A1 (fr) 2018-05-31
US20180002313A1 (en) 2018-01-04
LT3024826T (lt) 2019-02-25
US20200262816A1 (en) 2020-08-20
CU20160010A7 (es) 2016-06-29
EP3024826A1 (en) 2016-06-01
HK1218754A1 (zh) 2017-03-10
US11028070B2 (en) 2021-06-08
JO3457B1 (ar) 2020-07-05
WO2015011164A1 (en) 2015-01-29
MX365373B (es) 2019-05-31
HK1222856A1 (en) 2017-07-14
KR20160033224A (ko) 2016-03-25
PH12016500034A1 (en) 2016-03-28
JP6395829B2 (ja) 2018-09-26
HRP20190277T1 (hr) 2019-04-05
PH12016500034B1 (en) 2016-03-28
CR20160030A (es) 2016-03-09
MD4793C1 (ro) 2022-09-30
TN2016000003A1 (en) 2017-07-05
US10689364B2 (en) 2020-06-23
AP2016008989A0 (en) 2016-01-31
CN105431422A (zh) 2016-03-23
MA38801B1 (fr) 2019-03-29
US9809574B2 (en) 2017-11-07
CA2919572A1 (en) 2015-01-29
EA201600122A1 (ru) 2016-07-29
FR3008977A1 (fr) 2015-01-30
JP2016525529A (ja) 2016-08-25
GEP20207070B (en) 2020-02-25
RS58344B1 (sr) 2019-03-29
BR112016001080B1 (pt) 2022-04-05
UA117490C2 (uk) 2018-08-10
AU2014295101B2 (en) 2018-05-31
SG11201600205XA (en) 2016-02-26
MY193619A (en) 2022-10-20
TR201819155T4 (tr) 2019-01-21
IL243449A0 (en) 2016-02-29
DK3024826T3 (en) 2019-03-04
AR097009A1 (es) 2016-02-10
KR102008431B1 (ko) 2019-08-07
BR112016001080A2 (ro) 2017-07-25
EP3024826B1 (en) 2018-11-14
MD4793B1 (ro) 2022-02-28
RU2689305C2 (ru) 2019-05-27
PE20160241A1 (es) 2016-04-30
SI3024826T1 (sl) 2019-03-29

Similar Documents

Publication Publication Date Title
MD20160018A2 (ro) Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201692269A1 (ru) Новые композиции, их использование и способы получения
GEP20207056B (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
GB201209613D0 (en) New compounds
TN2015000278A1 (en) Autotaxin inhibitors
TW201613901A (en) New compounds
MD4516B1 (ro) Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201492002A1 (ru) Противовирусные соединения
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
IN2014MN00988A (ro)
MD4575B1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MX349004B (es) Nuevos compuestos.
MX366899B (es) Nuevos compuestos.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
EA201600288A1 (ru) Замещенные фенилаланиновые производные

Legal Events

Date Code Title Description
FG4A Patent for invention issued
HK9A Erratum in official gazette with regard to application (patent for invention)

Free format text: RECTIFICATION IN INID 13

TK4A Erratum in official gazette in regard to patent for invention

Free format text: RECTIFICATION IN INID 13

KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)